Riders · Health and Human Services Commission · Article II: Health and Human Services
Vendor Drug Rebates and Report
Rider 125 in the 2026-27 Act, page II-85
2028-29 request. Health and Human Services Commission has asked to revise this rider. What it asked for. A request, not law.
Through the session
- 2024-25 Act In current law rider 114
- Introduced (Senate) Amended rider 94
- Introduced (House) Amended rider 93
- Senate substitute Unchanged rider 94
- House substitute Unchanged rider 93
- House passed Unchanged rider 93
- Conference Unchanged rider 125
- 2026-27 Act Unchanged rider 125
Pick any two steps to compare their wording.
What changed in the text
2024-25 Act → Introduced (House): 20 passages changed.
Removed words are struck through; added words are underlined. Sources: 2024-25 Act · Introduced (House).
Every version: numbers, statuses and source pages
| Version | Rider | Against the version before | Against the current budget | Source |
|---|---|---|---|---|
| 2024-25 ActGeneral Appropriations Act, 2024-25 Biennium | 114 | First version | — | Page II-84 |
| Introduced (Senate)Senate Bill 1 as introduced (LBB recommended, Senate) | 94 was 114 | Amended | — | Page II-95 |
| Introduced (House)House Bill 1 as introduced (LBB recommended, House) | 93 was 114 | Amended | — | Page II-94 |
| Senate substituteCommittee Substitute for Senate Bill 1 | 94 | Unchanged | Amended | Page II-76 |
| House substituteHouse Committee Substitute for Senate Bill 1 | 93 was 94 | Unchanged | Amended | Page II-74 |
| House passedSenate Bill 1 as passed the second house | 93 | Unchanged | Amended | Page II-74 |
| ConferenceConference Committee Report for Senate Bill 1 | 125 was 93 | Unchanged | Amended | Page II-85 |
| 2026-27 ActGeneral Appropriations Act, 2026-27 Biennium | 125 | Unchanged | Amended | Page II-85 |
Full text of each wording
Introduced (Senate), Introduced (House), Senate substitute, House substitute, House passed, Conference, 2026-27 Act
Source, page II-85Vendor Drug Rebates and Report. All references in this rider to rebate revenue refer to vendor drug rebates as well as supplemental rebates earned via the preferred drug lists (methods of finance include Vendor Drug Rebates-Medicaid No. 706, Vendor Drug Rebates-CHIP No. 8070, Vendor Drug Rebates-Supplemental Rebates No. 8081, and Vendor Drug Rebates-Public Health No. 8046).
(a) Rebates as a First Source of Funding. As rebates are generated, expenditures to support prescription drugs in Medicaid, Children's Health Insurance Program (CHIP), Healthy Texas Women (HTW), Children with Special Health Care Needs (CSHCN), and Kidney Health Care (KHC) shall be made from rebate revenues. In the event rebate revenues are not available for expenditure, appropriations from the General Revenue Fund may be used to support prescription drug expenditures until rebate revenues are available.
(b) Appropriation of Medicaid and CHIP Rebates. In addition to rebate revenues appropriated above in Strategies A.1.1, Medicaid Client Services, and C.1.1, CHIP, the Health and Human Services Commission (HHSC) is appropriated Medicaid and CHIP vendor drug rebates generated in excess of those amounts, subject to the following requirements:
(1) Vendor drug rebates shall be expended prior to utilization of any appropriations from the General Revenue Fund available for the purpose of Medicaid and CHIP prescription drugs.
(2) In the event appropriations from the General Revenue Fund has been expended prior to the receipt of vendor drug rebates, HHSC shall reimburse General Revenue. HHSC shall reimburse the General Revenue Fund with vendor drug rebates on a monthly basis.
(3) Program Benefit Agreement revenues collected in lieu of state supplemental rebates will be expended prior to utilization of any appropriations from the General Revenue Fund available for the purpose of the Medicaid program specified in the Agreement.
(c) Appropriation of HTW, CSHCN, and KHC Rebates. In addition to rebate revenue appropriated above in Strategies D.1.1, Women's Health Programs; D.1.7, Children with Special Needs; and D.1.9, Kidney Health Care, HHSC is appropriated vendor drug rebates generated in excess of those amounts, subject to the following requirements:
(1) Vendor drug rebates shall be expended prior to utilization of any appropriations from the General Revenue Fund appropriated for the purpose of operating the HTW, CSHCN, and KHC programs.
(2) In the event appropriations from the General Revenue Fund are expended prior to the receipts of vendor drug rebates, HHSC shall reimburse the General Revenue Fund. HHSC shall reimburse the General Revenue Fund with vendor drug rebates on a monthly basis.
(3) In the event HHSC expends vendor drug rebates in excess of amounts appropriated above in Strategies D.1.1, Women's Health Programs; D.1.7, Children with Special Needs; and D.1.9, Kidney Health Care, General Revenue Fund appropriations are reduced by a like amount.
(d) Limited Use of Rebates. Rebates generated by a specific program shall only be used for that specific program.
(e) Performance Reporting for the Prescription Drug Rebate Program. HHSC shall report on an annual basis the following information to the Legislative Budget Board, the State Auditor's Office, the Comptroller of Public Accounts and the Office of the Governor: the outstanding prescription drug rebate balances for the Medicaid, CHIP, HTW, CSHCN, and KHC. The report shall include rebate principal and interest outstanding, age of receivables, and annual collection rates. The reports shall specify amounts billed, dollar value of pricing and utilization adjustments, and dollars collected. HHSC shall report these data on each fiscal year for which the Prescription Drug Rebate program has collected rebates and also on a cumulative basis for the last five fiscal years.
2024-25 Act
Source, page II-84Vendor Drug Rebates and Report. All references in this rider to rebate revenue refer to vendor drug rebates as well as supplemental rebates earned via the preferred drug lists (methods of finance include Vendor Drug Rebates-Medicaid No. 706, Vendor Drug Rebates-CHIP No. 8070, Vendor Drug Rebates-Supplemental Rebates No. 8081, and Vendor Drug Rebates-Public Health No. 8046).
(a) Rebates as a First Source of Funding. As rebates are generated, expenditures to support prescription drugs in Medicaid, CHIP, Healthy Texas Women (HTW), Children with Special Health Care Needs (CSHCN), and Kidney Health Care (KHC) shall be made from rebate revenues. In the event rebate revenues are not available for expenditure, General Revenue may be used to support prescription drug expenditures until rebate revenues are available.
(b) Appropriation of Medicaid and CHIP Rebates. In addition to rebate revenues appropriated above in Strategies A.1.6, Medicaid Prescription Drugs, and C.1.1, CHIP, the Health and Human Services Commission (HHSC) is appropriated Medicaid and CHIP vendor drug rebates generated in excess of those amounts, subject to the following requirements:
(1) Vendor drug rebates shall be expended prior to utilization of any General Revenue available for the purpose of Medicaid and CHIP prescription drugs.
(2) In the event General Revenue has been expended prior to the receipt of vendor drug rebates, HHSC shall reimburse General Revenue. HHSC shall reimburse the General Revenue Fund with vendor drug rebates on a monthly basis.
(3) Program Benefit Agreement revenues collected in lieu of state supplemental rebates will be expended prior to utilization of any General Revenue available for the purpose of the Medicaid program specified in the Agreement.
(c) Appropriation of HTW, CSHCN, and KHC Rebates. In addition to rebate revenue appropriated above in Strategies D.1.1, Women's Health Programs; D.1.7, Children with Special Needs; and D.1.9, Kidney Health Care, HHSC is appropriated vendor drug rebates generated in excess of those amounts, subject to the following requirements:
(1) Vendor drug rebates shall be expended prior to utilization of any General Revenue appropriated for the purpose of operating the HTW, CSHCN, and KHC programs.
(2) In the event General Revenue is expended prior to the receipts of vendor drug rebates, HHSC shall reimburse General Revenue. HHSC shall reimburse the General Revenue with vendor drug rebates on a monthly basis.
(3) In the event HHSC expends vendor drug rebates in excess of amounts appropriated above in Strategies D.1.1, Women's Health Programs; D.1.7, Children with Special Needs; and D.1.9, Kidney Health Care, General Revenue appropriations are reduced by a like amount.
(d) Limited Use of Rebates. Rebates generated by a specific program shall only be used for that specific program.
(e) Performance Reporting for the Prescription Drug Rebate Program. HHSC shall report on an annual basis the following information to the Legislative Budget Board, the State Auditor's Office, the Comptroller of Public Accounts and the Office of the Governor: the outstanding prescription drug rebate balances for the Medicaid, CHIP, HTW, CSHCN, and KHC. The report shall include rebate principal and interest outstanding, age of receivables, and annual collection rates. The reports shall specify amounts billed, dollar value of pricing and utilization adjustments, and dollars collected. HHSC shall report these data on each fiscal year for which the Prescription Drug Rebate program has collected rebates and also on a cumulative basis for the last five years.